Prothena Corp. Public Ltd. Co. PRTA
Biotechnology: Pharmaceutical Preparations · data as of November 13, 2026
Prothena Corp. Public Ltd. Co. (PRTA) is a healthcare company listed in the US with a market value of about $419M. In the twelve months to September 30, 2026 it had revenue of $53M and net income of -$24M, a net margin of -45.4%.
Its overall Stock Analiz score is 0.8 out of 5 (weak). The strongest part is financial health (2/5); the weakest is value (0/5).
Key numbers: 5-year revenue growth of 63% a year, a 5-year average ROIC of -25%.
About Prothena Corp. Public Ltd.
Prothena Corp. Public Ltd. is listed in the US and classified in biotechnology: pharmaceutical preparations. Revenue went from $51M in 2014 to $10M in 2025, a decline of about 14.0% a year. It was profitable in 1 of the last 10 years in our data. Its share count rose by 14% over three years (dilution for shareholders). It spends 1393% of revenue on research and development.
Score: 0.8 / 5
Checks passed
- Strong R&D investment or growth above 20%
- 5-year revenue growth above 8% a year
- More cash than debt, or low debt to equity
- Liabilities below 60% of assets
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $53M | $10M | $135M | $91M | $54M | $201M | $853000 | $814000 | $955000 | $28M | $1M |
| Net income | -$24M | -$244M | -$122M | -$147M | -$117M | $67M | -$111M | -$78M | -$156M | -$153M | -$160M |
| Free cash flow | -$31M | -$164M | -$150M | -$134M | -$109M | $93M | -$80M | -$53M | — | — | — |
| EPS (diluted) | $-0.45 | $-4.53 | $-2.27 | $-2.76 | $-2.47 | $1.38 | $-2.78 | $-1.95 | $-3.93 | $-4.07 | $-4.66 |
| Net margin | -45.4% | -2520.6% | -90.5% | -160.9% | -217.0% | 33.4% | -13029.8% | -9542.6% | -16297.9% | -556.8% | -15176.1% |
| ROIC | — | -58.7% | -29.5% | -30.5% | -19.5% | 14.0% | -55.7% | -22.9% | -49.0% | -37.1% | -34.5% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 5 analysts is $21.40, 162% above the current price; targets range from $8.00 to $36.00; the consensus rating is “Buy”; expected EPS is $0.66 for the fiscal year ending December 31, 2026.
Frequently asked questions
Does Prothena Corp. Public Ltd. pay a dividend?
Not currently.
Is Prothena Corp. Public Ltd. a good stock to buy?
We do not give buy or sell advice. Prothena Corp. Public Ltd. scores 0.8 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.